Clinical trial
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With…
NCT00410553 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00410553 |
|---|---|
| Title | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery |
| Official title | A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7 |
| Intervention type | Drug |
| Interventions | Eribulin Mesylate, Gemcitabine Hydrochloride |
| Enrollment | 45 |
| Start date | Nov 14, 2006 |
| Primary completion | Oct 24, 2012 |
| Completion | Oct 24, 2012 |
| First posted | Dec 13, 2006 |
| Last update posted | Oct 3, 2018 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: